ONCOLOGY: Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma

Audio Journal of Oncology, February 26th, 2008 Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma MARTIN DREYLING, University Hospital Grosshaden, Munich REFERENCE: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He gave Peter Goodwin his latest data on combination therapy using the antibody, rituximab, and the emerging rôles of other targeted agents.